Akums Drugs & Pharma Stock Price Analysis and Quick Research Report. Is Akums Drugs & Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Akums Drugs & Pharma. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Akums Drugs & Pharma has a PE ratio of $$PE_ratio$$ which is #if ( $$PE_ratio$$ > 15 ) then "high" else "low";# and comparatively #if ( $$PE_ratio$$ > 15 ) then "overvalued" else "undervalued";#.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Akums Drugs & Pharma has ROA of $$ROA_Per$$% which is a #if ( $$ROA_Per$$ > 15 ) then "good" else "bad";# sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Akums Drugs & Pharma has a Current ratio of $$Current_Ratio_x$$.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Akums Drugs & Pharma has a ROE of 13.1474%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Akums Drugs & Pharma has a Debt to Equity ratio of 0.0017 which means that the company has #if ( 0.0017 > 2 ) then "high" else "low";# proportion of debt in its capital.

• Sales growth: Akums Drugs & Pharma has reported revenue growth of $$NetSales_Growth_Y_1$$% which is #if( $$NetSales_Growth_Y_1$$ > 15 ) then "fair" else "poor";# in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Akums Drugs & Pharma for the current financial year is 10.2632750513804%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Akums Drugs & Pharma is Rs $$DPS_PCF_Y_1$$ and the yield is $$TTM_YIELD$$%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Akums Drugs & Pharma is Rs $$TTMEPS_Y_1$$. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Akums Drugs & Pharma in Ticker for free. Also, one can get the intrinsic value of Akums Drugs & Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Akums Drugs & Pharma FAQs

Q1. What is Akums Drugs & Pharma share price today?
Ans: The current share price of Akums Drugs & Pharma is Rs 454.25.

Q2. What is the market capitalisation of Akums Drugs & Pharma?
Ans: Akums Drugs & Pharma has a market capitalisation of Rs $$Market_Capitalisation$$ Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Akums Drugs & Pharma?
Ans: The PE ratio of Akums Drugs & Pharma is $$PE_ratio$$ and the P/B ratio of Akums Drugs & Pharma is $$PB_ratio$$, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Akums Drugs & Pharma share?
Ans: The 52-week high share price of Akums Drugs & Pharma is Rs $$All_High$$, and the 52-week low share price of Akums Drugs & Pharma is Rs $$All_Low$$.

Q5. Does Akums Drugs & Pharma pay dividends?
Ans: Currently, Akums Drugs & Pharma #if ( $$TTM_YIELD$$ > 0 ) then "pays" else "does not pay";# dividends. Dividend yield of Akums Drugs & Pharma is around $$TTM_YIELD$$%.

Q6. What are the face value and book value of Akums Drugs & Pharma shares?
Ans: The face value of Akums Drugs & Pharma shares is Rs $$FV_Y_1$$, while the book value per share of Akums Drugs & Pharma is around Rs $$TTMBook_NAV_Share$$. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Akums Drugs & Pharma?
Ans: Akums Drugs & Pharma has a total debt of Rs $$Total_Debt$$ Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Akums Drugs & Pharma?
Ans: The ROE of Akums Drugs & Pharma is 13.1474% and ROCE of Akums Drugs & Pharma is $$ROCE_Y_1$$%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Akums Drugs & Pharma a good buy for the long term?
Ans: The Akums Drugs & Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Akums Drugs & Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Akums Drugs & Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Akums Drugs & Pharma’s financials?
Ans: You can review Akums Drugs & Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.